Qualcomm announces Snapdragon 835, built on Samsung’s 10nm process

Samsung Electronics originally announced that it was building the industry’s first 10nm mobile application processor back in October and today the company has confirmed that it is indeed manufacturing Qualcomm’s next generation Snapdragon processor. However, the processor breaks slightly from previous naming conventions, as it is called the Snapdragon 835, rather than the 830 that many had expected.

At a press event in New York, the two companies jointly announced that Qualcomm’s Snapdragon 835 will be manufactured on Samsung’s cutting edge 10-nanometer FinFET process. This decision will bring both performance and energy efficiency improvements to Qualcomm’s next generation processor, when compared with the 14nm FinFET node from Samsung used for this year’s Snapdragon 820 and 821.

“Using the new 10nm process node is expected to allow our premium tier Snapdragon 835 processor to deliver greater power efficiency and increase performance while also allowing us to add a number of new capabilities that can improve the user experience of tomorrow’s mobile devices.” – Keith Kressin, senior vice president, product management, Qualcomm Technologies

According to Samsung, the move to 10nm provides a 30 percent increase to area efficiency, combined with up to a 27 percent boost to performance or a 40 percent reduction in power consumption. Of course, these results will vary based on the processor’s architecture and real world usage, but these are nonetheless promising statistics for next year’s smartphones.

For Samsung, confirmation that it will be fulfilling orders for another generation of flagship Qualcomm processor, which will more than likely be powering a large number of flagship smartphones next year, is good news for Samsung Semiconductor.

The company’s semiconductor division has become an increasingly important contributor to Samsung’s profitability, as smartphone sales will take a hit this year following the Galaxy Note 7 saga and Galaxy smartphone sales growth has slowed.

Comments

The Secret Science 02:The 30 Most Disturbing Human Experiments in History

Disturbing human experiments aren’t something the average person thinks too much about. Rather, the progress achieved in the last 150 years of human history is an accomplishment we’re reminded of almost daily. Achievements made in fields like biomedicine and psychology mean that we no longer need to worry about things like deadly diseases or masturbation as a form of insanity. For better or worse, we have developed more effective ways to gather information, treat skin abnormalities, and even kill each other. But what we are not constantly reminded of are the human lives that have been damaged or lost in the name of this progress. The following is a list of the 30 most disturbing human experiments in history. 30. The Tearoom Sex Study Sociologist Laud Humphreys often wondered about the men who commit impersonal sexual acts with one another in public restrooms. He wondered why “tearoom sex” — fellatio in public restrooms — led to the majority of homosexual arrests in ...

The Strange and Stranger Case of Wyndham Lathem

A Northwestern University plague researcher has been charged with a brutal murder. Here’s what we know about him. WIKIMEDIA, TONY WEBSTER O n July 27, The Chicago Tribune reported that there was an arrest warrant issued for Wyndham Lathem , a microbiologist at Northwestern University. The crime Lathem would later be charged with was brutal—26-year-old Trenton James Cornell-Duranleau, whose body was found in Lathem’s apartment, had been stabbed dozens of times. But Lathem was nowhere to be found. As events unfolded over the following days, it became clear he had fled from Chicago to California with a second suspect, 56-year-old Andrew Warren, a University of Oxford employee from the United Kingdom visiting the states. Along the way, the two men apparently made an anonymous $1,000 donation in Cornell-Duranleau’s name to the Lake Geneva Public Library and another donation for $5,610 to a Chicago health center. Lathem had also sent a video to fa...

Popular painkiller doesn’t have more heart risks than others, study claims

NEW ORLEANS — A long-awaited study on painkillers called nonsteroidal anti-inflammatory drugs, the most widely prescribed class of drugs in the world, has concluded that the three most commonly used carry a similar risk of cardiovascular complications. Yet critics say the study was too flawed to fairly compare them. Concerns about a type of NSAID called COX-2 inhibitors peaked in 2004 when the drug Vioxx was withdrawn from the market — a decision steeped in scandal because manufacturer Merck & Co had initially hidden data that would reveal the drug’s cardiovascular risks. A second COX-2 inhibitor, Pfizer Inc.’s Celebrex, was allowed to remain on the market with the condition that Pfizer conduct a study to prove that Celebrex was no worse than two older NSAIDs, naproxen and ibuprofen. The study lasted 10 years and enrolled more than 24,000 patients, but faced challenges. Doctors in European Union countries would not participate because they were worried a...

The Research

Search This Blog